Adoram Therapeutics
Startup
Summarized by Halo AI
Adoram Therapeutics is a Swiss biotech spin-off from the University of Geneva developing allosteric small molecule drugs for cancer and immune-based diseases, with a primary focus on A2AR inhibitors for solid tumor immunotherapy.
Founded & HQ
Grand-Lancy, Geneva, Switzerland
Company size
1-10 employees
Funding
~$3.8M
IP status
1 patent filed · 3 grants confirmed
Activity highlights
Secured a European patent in August 2025 for its A2AR NAM solid tumor immunotherapy and a pre-seed investment round in February 2025
Adoram Therapeutics is a biotech company specializing in allosteric immunotherapies for cancer and immune diseases, with a focus on safer, more potent small molecule drugs.
AI summary generated on Jun 22, 2026
OpenAlex
OpenAlexFor general inquiries
DP
Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.